EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years

Anouk Achten, Vanessa P M van Empel, Jerremy Weerts, Sanne Mourmans, Fabienne Beckers-Wesche, Mireille Spanjers, Arno Gingele, Hans-Peter Brunner-La Rocca, Sandra Sanders-van Wijk, Christian Knackstedt

Heart and Vessels · 2024-10 · 39 (10) · 857-866

DOI: 10.1007/s00380-024-02408-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Heart and Vessels, online erschienen am 06.05.2024. Verfasst von Anouk Achten und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202, AZ, …. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Health Research Foundation, AstraZeneca Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) has increased over the years due to diagnostic and therapeutic developments. Timely initiation of novel disease-modifying treatments improves both morbidity and mortality, which underlines the necessity for a prompt diagnosis. Nevertheless, early diagnosis of ATTR-CM remains challenging. This is a retrospective observational cohort study of patients diagnosed with ATTR-CM. Between 2016 and 2023, 87 patients were diagnosed with cardiac amyloidosis of which 65 (75%) patients with ATTR-CM and 22 (25%) patients with light chain amyloidosis. This study included 65 ATTR-CM patients (mean age 77 ± 7 years; 86% male) of whom 59 (91%) with wild-type ATTR-CM (ATTRwt) and six (9%) with variant ATTR-CM. We observed a surge in ATTR-CM diagnoses from 3 patients/year (2016–2020) to 16 patients/year (2021–2023), driven by ATTRwt. Nevertheless, the interval between the onset of heart failure symptoms and ATTR-CM diagnosis has not changed significantly (2016–2020 27.3 months [18.6–62.4]; 2021–2023 30.0 months [8.6–57.2]; p = 0.546), driven by time to referral. Red flags for ATTR-CM preceded diagnosis by several years: left ventricular hypertrophy (79%, 5.8 years [3.3–7.0]) and carpal tunnel syndrome (49%, 6.8 years [2.3–12.1]). Despite the presence of typical red flags, symptom-to-diagnosis duration has remained similar driven by time to referral. Improved recognition of red flags for ATTR-CM could reduce the time to diagnosis and improve overall recognition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHumansMaleFemaleAgedRetrospective StudiesTime FactorsEarly DiagnosisAged, 80 and overEchocardiographyPrealbumin

Stichwörter der Autor:innen

Cardiac amyloidosisDiagnostic delayDiagnostic trajectoryHeart failureTransthyretin amyloidosis

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202, AZ, Maastricht, The Netherlands. anouk.achten@mumc.nl.
  • Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands. anouk.achten@mumc.nl.
  • Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202, AZ, Maastricht, The Netherlands.
  • Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.

Förderung

  • Pfizer Health Research Foundation
  • AstraZeneca Foundation

Zitieren

APA

Achten, A., van Empel, V. P. M., Weerts, J., Mourmans, S., Beckers-Wesche, F., Spanjers, M., Gingele, A., Brunner-La Rocca, H. P., Sanders-van Wijk, S., & Knackstedt, C. (2024). Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years. Heart and Vessels, 39(10), 857-866. https://doi.org/10.1007/s00380-024-02408-3

Vancouver

Achten A, van Empel VPM, Weerts J, Mourmans S, Beckers-Wesche F, Spanjers M, et al. Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years. Heart and Vessels. 2024;39(10):857-866. doi:10.1007/s00380-024-02408-3

BibTeX
@article{Achten2024,
  author = {Achten, Anouk and van Empel, Vanessa P M and Weerts, Jerremy and Mourmans, Sanne and Beckers-Wesche, Fabienne and Spanjers, Mireille and Gingele, Arno and Brunner-La Rocca, Hans-Peter and Sanders-van Wijk, Sandra and Knackstedt, Christian},
  title = {Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years},
  journal = {Heart and Vessels},
  year = {2024},
  volume = {39},
  number = {10},
  pages = {857--866},
  doi = {10.1007/s00380-024-02408-3}
}
Kostenlos starten →